Skip to content

INOVIO PHARMACEUTICALS, INC.: 10-Q filed 2026-08-12

What INOVIO PHARMACEUTICALS, INC. reported in its quarterly report filed 2026-08-12 (fiscal Q2 2026): 35 published measures, 101 facts as tagged in accession 0001055726-26-000023.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-12
Fiscal period
fiscal Q2 2026
Accession
0001055726-26-000023 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All INOVIO PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-3049,389,494USD
At 2025-12-3174,310,035USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-3045,018,411USD
At 2025-12-3150,213,759USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-304,371,083USD
At 2026-03-316,067,882USD
At 2025-12-3124,096,276USD
At 2025-06-3028,530,905USD
At 2025-03-3151,250,724USD
At 2024-12-3168,503,795USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-3031,526,164USD
At 2025-12-3144,273,319USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-6,012,458USD91
2026-01-01 to 2026-06-30-25,695,256USD181
2026-01-01 to 2026-03-31-19,682,798USD90
2025-04-01 to 2025-06-30-23,519,412USD91
2025-01-01 to 2025-06-30-43,214,109USD181
2025-01-01 to 2025-03-31-19,694,697USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-39,638,543USD181
2025-01-01 to 2025-06-30-47,685,386USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2026-01-01 to 2026-06-300USD181
2025-01-01 to 2025-06-3090,303USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD91
2026-01-01 to 2026-06-300USD181
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-3065,343USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-3018,108,851USD181
2025-01-01 to 2025-06-30993,153USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-308,782,537USD181
2025-01-01 to 2025-06-305,230,313USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-1,840,860,419USD
At 2025-12-31-1,815,165,163USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-3081,619,113shares91
2026-01-01 to 2026-06-3075,395,090shares181
2025-04-01 to 2025-06-3038,830,053shares91
2025-01-01 to 2025-06-3038,722,451shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-3081,619,113shares91
2026-01-01 to 2026-06-3075,395,090shares181
2025-04-01 to 2025-06-3038,830,053shares91
2025-01-01 to 2025-06-3038,722,451shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.07USD/shares91
2026-01-01 to 2026-06-30-0.34USD/shares181
2025-04-01 to 2025-06-30-0.61USD/shares91
2025-01-01 to 2025-06-30-1.12USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.07USD/shares91
2026-01-01 to 2026-06-30-0.34USD/shares181
2025-04-01 to 2025-06-30-0.61USD/shares91
2025-01-01 to 2025-06-30-1.12USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-301,888,725USD
At 2025-12-312,527,603USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-301,467,181USD181
2025-01-01 to 2025-06-302,234,141USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-18,624,522USD91
2026-01-01 to 2026-06-30-40,574,515USD181
2025-04-01 to 2025-06-30-23,084,519USD91
2025-01-01 to 2025-06-30-48,135,048USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-3039,913,249USD
At 2025-12-3161,123,346USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-3039,915,059USD
At 2025-12-3143,668,555USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-3018,624,522USD91
2026-01-01 to 2026-06-3040,574,515USD181
2025-04-01 to 2025-06-3023,084,519USD91
2025-01-01 to 2025-06-3048,200,391USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-3010,826,549USD91
2026-01-01 to 2026-06-3024,896,656USD181
2025-04-01 to 2025-06-3014,521,407USD91
2025-01-01 to 2025-06-3030,612,309USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-3082,341,945shares
At 2025-12-3168,996,647shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-3031,526,164USD
At 2025-12-3144,273,319USD
At 2025-06-3024,351,377USD
At 2024-12-3165,813,297USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-301,845,429,136USD
At 2025-12-311,839,830,405USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30-279,976USD
At 2025-12-31-637,963USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-06-305,670,451USD
At 2025-12-316,542,923USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-06-308,002,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2026-06-301,917,069USD
At 2025-12-312,012,475USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-303,239,232USD
At 2025-12-312,610,882USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-5,656,341USD91
2026-01-01 to 2026-06-30-25,337,269USD181
2025-04-01 to 2025-06-30-23,519,834USD91
2025-01-01 to 2025-06-30-43,200,184USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-307,797,973USD91
2026-01-01 to 2026-06-3015,677,859USD181
2025-04-01 to 2025-06-308,563,112USD91
2025-01-01 to 2025-06-3017,588,082USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-01-01 to 2026-06-30638,878USD181
2025-01-01 to 2025-06-30727,518USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,714,620USD91
2026-01-01 to 2026-06-30-2,000,110USD181
2025-04-01 to 2025-06-30-703,183USD91
2025-01-01 to 2025-06-30-703,665USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2026-01-01 to 2026-06-304,331,095USD181
2025-01-01 to 2025-06-301,102,149USD181

Inspect the source

Entity
INOVIO PHARMACEUTICALS, INC. / CIK 0001055726
Captured
2026-09-20T05:17:43.559Z
SEC response SHA-256
9bfa830827e08b2d190e6d0b4ce0274a3c0d8852b6e536b16b5cfeadcaa54cf9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001055726.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))